Reaction rate parameter value for phosphate with transfer with respect to ATP
|
None
|
81.0
nM
|
|
Reaction rate parameter value for phosphate with transfer with respect to ATP
|
None
|
307.0
nM
|
|
Reaction rate parameter value for phosphate with transfer with respect to ATP
|
None
|
37.0
nM
|
|
Inhibition of DNA gyrase supercoiling in Escherichia coli.
|
Escherichia coli
|
47.0
ug.mL-1
|
|
In vitro antibacterial activity was determined as inhibitory concentration causing 50% DNA-gyrase supercoiling inhibition (SCI)
|
Escherichia coli
|
3.3
ug.mL-1
|
|
In vitro inhibitory activity against protein kinase A
|
unidentified
|
600.0
nM
|
|
Tested for in vitro inhibitory activity against tyrosine protein kinase pp60 c-src
|
None
|
300.0
nM
|
|
Inhibition of rat liver CK2
|
Rattus norvegicus
|
20.0
nM
|
|
Inhibition of rat liver CK2
|
Rattus norvegicus
|
40.0
nM
|
|
Antiproliferative activity against SUDHL1 expressing NPM-ALK by MTT assay
|
None
|
85.0
%
|
|
Antiproliferative activity against FEPD by MTT assay
|
Homo sapiens
|
70.0
%
|
|
Antiproliferative activity against KARPAS299 expressing NPM-ALK by MTT assay
|
None
|
60.0
%
|
|
Antiproliferative activity against SR786 expressing NPM-ALK by MTT assay
|
None
|
40.0
%
|
|
Inhibition of CK2 in rat liver
|
Rattus norvegicus
|
40.0
nM
|
|
Inhibition of H(+)/K(+) ATPase from pig gastric mucosa
|
Sus scrofa
|
210.0
nM
|
|
Inhibition of rat liver CK2 by Lineweaver-Burke double reciprocal plot analysis
|
Rattus norvegicus
|
20.0
nM
|
|
Inhibition of rat liver CK2 catalytic activity
|
Rattus norvegicus
|
40.0
nM
|
|
Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)
|
Homo sapiens
|
40.0
nM
|
|
Inhibition of Saccharomyces cerevisiae fatty acid synthase
|
Saccharomyces cerevisiae
|
20.0
ug.mL-1
|
|
Antifungal activity against Candida albicans ATCC 90028
|
Candida albicans
|
50.0
ug.mL-1
|
|
Antifungal activity against Cryptococcus neoformans ATCC 90113
|
Cryptococcus neoformans
|
5.5
ug.mL-1
|
|
Antiplasmodial activity after 24 hrs against chloroquine-sensitive, mefloquine-resistant Plasmodium falciparum D6 infected human erythrocytes by [G-3H]hypoxanthine uptake
|
Plasmodium falciparum D6
|
0.145
ug.mL-1
|
|
Antiplasmodial activity after 24 hrs against chloroquine-resistant, mefloquine-sensitive Plasmodium falciparum W2 infected human erythrocytes by [G-3H]hypoxanthine uptake
|
Plasmodium falciparum
|
0.103
ug.mL-1
|
|
Inhibition of HIV1 RT
|
Human immunodeficiency virus 1
|
150.0
ug.mL-1
|
|
Antiinflammatory activity in human neutrophils assessed as respiratory burst inhibition at 1000 ug/ml by WST-1 assay
|
Homo sapiens
|
27.1
%
|
|
PUBCHEM_BIOASSAY: SMAD Transcription Factor Inhibitors Dose Response Confirmation. (Class of assay: confirmatory) [Related pubchem assays: 630 (Primary screen preceding this dose response confirmation assay.)]
|
Homo sapiens
|
142.0
nM
|
|
PUBCHEM_BIOASSAY: High Throughput Screening Assay for Hsp70 Inhibitors. (Class of assay: confirmatory) [Related pubchem assays: 786 ]
|
Homo sapiens
|
760.0
nM
|
|
PUBCHEM_BIOASSAY: Fluorescence polarization-based biochemical high throughput dose response assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1). (Class of assay: confirmatory) [Related pubchem assays: 1963 (Summary AID.), 1962 (Primary screen (TPT1 inhibitors).), 2153 (Counterscreen (RNase inhibitors).), 2149 (Confirmation screen (TPT1 inhibitors).)]
|
Candida albicans SC5314
|
540.68
nM
|
|
Antiplasmodial activity against Plasmodium falciparum F32
|
Plasmodium falciparum
|
330.0
nM
|
|
Antiplasmodial activity against Plasmodium falciparum Dd2
|
Plasmodium falciparum
|
105.0
nM
|
|
Antiplasmodial activity against Plasmodium falciparum FcB1
|
Plasmodium falciparum FcB1/Columbia
|
300.0
nM
|
|
Antiplasmodial activity against Plasmodium falciparum W2
|
Plasmodium falciparum
|
330.0
nM
|
|
Antiplasmodial activity against Plasmodium falciparum FcM29
|
Plasmodium falciparum
|
180.0
nM
|
|
Antiplasmodial activity against Plasmodium vinckei petteri infected in Swiss mouse assessed as inhibition of parasite growth at 50 mg/kg/day, ip measured on day 4 postinfection
|
Plasmodium vinckei petteri
|
100.0
%
|
|
Antiplasmodial activity against Plasmodium vinckei petteri infected in Swiss mouse assessed as inhibition of parasite growth at 100 mg/kg/day, ip measured on day 5 postinfection
|
Plasmodium vinckei petteri
|
100.0
%
|
|
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7
|
Plasmodium falciparum
|
819.0
nM
|
|
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2
|
Plasmodium falciparum
|
351.0
nM
|
|
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1
|
Plasmodium falciparum K1
|
970.0
nM
|
|
PUBCHEM_BIOASSAY: uHTS absorbance assay for the identification of compounds that inhibit VHR1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1661, AID1878, AID1957, AID1958, AID1992, AID2004, AID2070, AID2074, AID2684]
|
Homo sapiens
|
980.0
nM
|
|
Antioxidant activity assessed as DPPH free radical scavenging activity
|
None
|
4.8
ug
|
|
Inhibition of human recombinant aldose reductase using D-glyceraldehyde as substrate preincubated for 10 mins before substrate addition measured for every 10 secs for 50 mins by spectrophotometry
|
Homo sapiens
|
200.0
nM
|
|
Inhibition of human recombinant ARK5 expressed in Sf9 cells assessed as autophosphorylation after 80 mins by scintillation counting
|
Homo sapiens
|
510.0
nM
|
|
Inhibition of human recombinant EGF-R expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting
|
Homo sapiens
|
690.0
nM
|
|
Inhibition of human recombinant IGF1R expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting
|
Homo sapiens
|
250.0
nM
|
|
Inhibition of human recombinant SRC expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting
|
Homo sapiens
|
800.0
nM
|
|
Inhibition of human recombinant VEGF-R2 expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting
|
Homo sapiens
|
790.0
nM
|
|
Inhibition of human recombinant INS-R expressed in Sf9 cells using poly(A,E,K,Y)6:2:5:1 as substrate after 80 mins by scintillation counting
|
Homo sapiens
|
340.0
nM
|
|
Inhibition of human recombinant MET expressed in Sf9 cells using poly(A,E,K,Y)6:2:5:1 as substrate after 80 mins by scintillation counting
|
Homo sapiens
|
580.0
nM
|
|
Inhibition of human recombinant TIE2 expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting
|
Homo sapiens
|
260.0
nM
|
|
Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay
|
Homo sapiens
|
110.0
nM
|
|
Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins
|
Homo sapiens
|
100.0
nM
|
|
TP_TRANSPORTER: inhibition of ochratoxin A uptake (ochratoxin A / 1uM) in Xenopus laevis oocytes
|
Xenopus laevis
|
270.0
nM
|
|
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method
|
Electrophorus electricus
|
-6.13
%
|
|
Inhibition of horse BChE at 2 mg/ml by Ellman's method
|
Equus caballus
|
4.4
%
|
|
Inhibition of Rattus norvegicus (rat) lens aldose reductase
|
Rattus norvegicus
|
199.53
nM
|
|
Inhibition of human recombinant CK2 expressed in Escherichia coli BL21(DE3) using RRRDDDSDDD as substrate after 15 mins by capillary electrophoretic analysis
|
Homo sapiens
|
40.0
nM
|
|
Inhibition of human recombinant CK2 expressed in Escherichia coli BL21(DE3) using RRRDDDSDDD as substrate at 10 uM after 15 mins by capillary electrophoretic analysis relative to control
|
Homo sapiens
|
95.0
%
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
75.25
%
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
65.47
%
|
|
Inhibition of sEH (unknown origin) assessed as substrate PHOME hydrolysis at 25 uM after 1 hr by fluorescence method
|
Homo sapiens
|
40.0
%
|
|
Inhibition of human recombinant CK2a1/CK2b holoenzyme expressed in Escherichia coli BL21(DE3) at 10 uM pre-incubated for 10 mins before substrate addition by capillary electrophoresis based assay
|
Homo sapiens
|
95.0
%
|
|
Inhibition of human recombinant CK2a1/CK2b holoenzyme expressed in Escherichia coli BL21(DE3) pre-incubated for 10 mins before substrate addition by capillary electrophoresis based assay
|
Homo sapiens
|
40.0
nM
|
|
Inhibition of CARM1 in human HeLa cells assessed as reduction of H3R17 methylation at 5 uM after 24 hrs by Western blot analysis relative to control
|
Homo sapiens
|
50.0
%
|
|
PubChem BioAssay. High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction. (Class of assay: confirmatory)
|
None
|
450.0
nM
|
|
Inhibition of human recombinant DNA polymerase iota expressed in Baculovirus expression system using TAMRA/BHQ-2-labeled primer/template measured at 2 to 6 mins by reporter-strand displacement assay
|
Homo sapiens
|
62.0
nM
|
|
Inhibition of human recombinant DNA polymerase eta expressed in Baculovirus expression system using TAMRA/BHQ-2-labeled primer/template measured at 2 to 6 mins by reporter-strand displacement assay
|
Homo sapiens
|
62.0
nM
|
|
Inhibition of wild type His-tagged translin/trax E126A mutant (unknown origin) coexpressed in Escherichia coli BL21 cells using RNase Alert as substrate at 30 uM incubated for 10 mins prior to substrate addition monitored over 60 mins by fluorescence assay
|
Homo sapiens
|
94.0
%
|
|
Inhibition of rat liver CK2 using RRRADDSDDDDD as substrate after 10 mins in presence of [gamma-33P]-ATP
|
Rattus norvegicus
|
40.0
nM
|
|
Inhibition of ELAV3 (unknown origin)-artificial ARE complex formation after 30 mins in the presence of biotin-labeled RNA probe by chemiluminescence nucleic acid detection method
|
Homo sapiens
|
600.0
nM
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
25.12
%
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
-0.73
%
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
8.04
%
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-7.36
%
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Staphylococcus aureus subsp. aureus
|
-17.94
%
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Acinetobacter baumannii
|
-6.11
%
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Escherichia coli
|
7.74
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
-5.38
%
|
|
Inhibition of CK2alpha (unknown origin)
|
Homo sapiens
|
20.0
nM
|
|
Inhibition of catalytic activity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293T cells and using 5-FAM labelled-EA2 peptide as substrate incubated for 30 mins by HPLC-based enzyme assay
|
Homo sapiens
|
510.0
nM
|
|
Binding affinity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293 cells assessed as dissociation constant by SPR analysis
|
Homo sapiens
|
371.0
nM
|
|
Binding affinity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293 cells assessed as dissociation rate by SPR analysis
|
Homo sapiens
|
8.79
10'-4/s
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
9.451
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.25
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.25
%
|
|
Inhibition of mouse CD73
|
Mus musculus
|
40.0
nM
|
|
Inhibition of mouse CD39
|
Mus musculus
|
500.0
nM
|
|
Inhibition of N-terminus hexa-histidine tagged-SARS-coV guanine-N7 methyltransferase expressed in Escherichia coli using GpppAUAU RNA as substrate incubated for 30 mins by liquid scintillation counting method
|
Severe acute respiratory syndrome-related coronavirus
|
19.0
nM
|
|